Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting learning session on first line management of ALK positive lung cancer.
In this webinar, a panel discussion would take place involving Dr. Jessicca Lin as the primary speaker and Dr. T. Raja, Dr. Amit Rauthan, Dr. B. K. Smruti and many other panelists who will share the important facts associated with first line management of ALK positive lung cancer.
Starting with the case scenario of non-small cell lung cancer, Dr Jessica has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, the panel discussion will give more knowledge.
ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.
Therefore, you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
How to keep your prostate healthy and lower your risk of developing serious problems
2.
Treatment of Smoldering Myeloma Cuts Progression Rate in Half
3.
PSA Testing Is Not Enough for Another Candidate for Prostate Cancer Screening.
4.
AI is useful in low-resource areas for triaging breast masses.
5.
Can Prior Authorization Be Better With Artificial Intelligence?
1.
RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health
2.
What Is A High MCV Level? Causes, Symptoms, And Treatment Options
3.
Revolutionizing Oncology: AI in Radiology, Machine Learning in Pathology, and Deep Learning for Cancer Detection
4.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
5.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
3.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
4.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation